Related Experiment Video
Updated: Jan 7, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Differential Expression of Key Oncogenic and Tumor Suppressor MicroRNAs Induced by Andrographolide in
Padmavati Sahare1, Luis Alberto Bravo-Vázquez2, Diego Antonio Veloz-Briones2
1Institute of Advanced Materials for Sustainable Manufacturing, Tecnologico de Monterrey, Campus Queretaro, Queretaro 76130, Mexico.
Background:
Prostate cancer remains a major contributor to cancer-related morbidity and mortality worldwide, emphasizing the need for safer and more effective therapeutic options. Andrographolide, a diterpenoid lactone derived from Andrographis paniculata, has shown promising anticancer activity, yet its effects on microRNA (miRNA) regulation in prostate cancer remain insufficiently explored.
Methods:
In this study, we evaluated the cytotoxic and molecular effects of andrographolide on two human prostate cancer cell lines, PC3 and LNCaP, along with HEK-293 cells as a noncancerous model.
Results:
Cell viability assessment using the MTT assay revealed dose-dependent cytotoxicity, with 24 h IC50 values of 82.31 µM for PC3, 68.79 µM for LNCaP, and 133.9 µM for HEK-293 cells. Subsequent expression analysis of key oncogenic and tumor suppressor miRNAs demonstrated that andrographolide induced the upregulation of miR-16-5p, miR-34a-5p, and miR-200a-5p miRNAs implicated in apoptosis, proliferation control, and androgen receptor signaling. In contrast, the expression of oncomiRs miR-21-5p and miR-221-5p showed minimal or nonsignificant changes, reflecting the complex and context-specific roles of miRNAs in prostate cancer. Gene expression profiling further indicated differential transcriptional responses between the two prostate cancer cell lines, consistent with their distinct molecular backgrounds.
Conclusions:
Although HEK-293 cytotoxicity and previously reported nephrotoxic effects warrant caution, these results support the potential of andrographolide as an adjuvant phytochemical capable of modulating clinically relevant miRNAs in prostate cancer. Future studies investigating optimized delivery systems and validating direct miRNA targets may help advance andrographolide toward safer and more targeted therapeutic applications.
Insights
Andrographolide shows potential as a prostate cancer treatment by altering microRNA (miRNA) expression, upregulating tumor suppressors. Further research is needed to optimize its use as a phytochemical adjuvant therapy.
Area of Science:
- Phytochemistry
- Molecular Oncology
- Cancer Therapeutics
Background:
- Prostate cancer poses a significant global health burden, necessitating novel therapeutic strategies.
- Andrographolide, a natural compound, exhibits anticancer properties, but its impact on microRNA (miRNA) regulation in prostate cancer is not well understood.
Purpose of the Study:
- To investigate the cytotoxic and molecular effects of andrographolide on prostate cancer cell lines.
- To explore andrographolide's influence on the expression of key microRNAs (miRNAs) in prostate cancer.
Main Methods:
- Cytotoxicity was assessed using MTT assays on PC3, LNCaP, and HEK-293 cells.
- MicroRNA (miRNA) and gene expression profiling were performed to analyze molecular changes induced by andrographolide.
Main Results:
- Andrographolide demonstrated dose-dependent cytotoxicity against prostate cancer cell lines (PC3, LNCaP).
- It upregulated tumor suppressor miRNAs (miR-16-5p, miR-34a-5p, miR-200a-5p) involved in apoptosis and proliferation.
- OncomiR expression (miR-21-5p, miR-221-5p) remained largely unchanged, indicating complex miRNA regulation.
Conclusions:
- Andrographolide shows promise as an adjuvant therapy for prostate cancer by modulating specific miRNAs.
- Caution is advised due to cytotoxicity in noncancerous cells and potential nephrotoxicity; further studies on delivery systems are warranted.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs